2016 Hematological Malignancies

Phase II Pivotal Study of BV Safety (AEs in ≥20% of pts)

Adverse event

All Grades (%)

Grade 3 (%)

Grade 4 (%)

Peripheral sensory neuropathy

47 46 42 37 36 29 22 22 21

9 2 0 0 1 2

0 0 0 0 0 0 6 0 0

Fatigue Nausea

Upper respiratory tract infection

Diarrhoea

Pyrexia

Neutropenia

14

Vomiting

0 0

Cough

Other grade 3/4 events in ≥5% of patients: • Thrombocytopenia: 8% • Anaemia: 6%

BV – Brentuximab Vedotin; AEs – adverse events; pts – patients

Adapted from Chen R et al; Blood, Nov 2012;120: 3689 (ASH abstract)